Humacyte Non Operating Income Net Other from 2010 to 2026
| HUMA Stock | USD 1.22 0.28 29.79% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 90.6 M | Current Value 75.8 M | Quarterly Volatility 10.5 M |
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.5 M, Interest Expense of 5.7 M or Selling General Administrative of 22.2 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or Days Sales Outstanding of 7.9. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
Humacyte | Non Operating Income Net Other | Build AI portfolio with Humacyte Stock |
Analyzing Humacyte's Non Operating Income Net Other over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Non Operating Income Net Other has evolved provides context for assessing Humacyte's current valuation and future prospects.
Latest Humacyte's Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Humacyte over the last few years. It is Humacyte's Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Humacyte Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 65,403,679 | |
| Geometric Mean | 64,689,624 | |
| Coefficient Of Variation | 16.06 | |
| Mean Deviation | 8,928,959 | |
| Median | 59,079,000 | |
| Standard Deviation | 10,502,960 | |
| Sample Variance | 110.3T | |
| Range | 31.6M | |
| R-Value | 0.77 | |
| Mean Square Error | 48.4T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | 1,595,575 | |
| Total Sum of Squares | 1765T |
Humacyte Non Operating Income Net Other History
About Humacyte Financial Statements
Humacyte stakeholders use historical fundamental indicators, such as Humacyte's Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Humacyte investors may analyze each financial statement separately, they are all interrelated. For example, changes in Humacyte's assets and liabilities are reflected in the revenues and expenses on Humacyte's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | 90.6 M | 75.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Humacyte is a strong investment it is important to analyze Humacyte's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Humacyte's future performance. For an informed investment choice regarding Humacyte Stock, refer to the following important reports:Check out the analysis of Humacyte Correlation against competitors. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. Market participants price Humacyte higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Humacyte assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Humacyte's market price often diverges from its book value, the accounting figure shown on Humacyte's balance sheet. Smart investors calculate Humacyte's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Humacyte's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.